Question 1

What is Biogen stock price today?

Accepted Answer

The current price of Biogen is 250.65 USD — it has increased by 2.52% in the past 24 hours. Watch Biogen stock price performance more closely on the advanced chart.

Question 2

What is Biogen stock ticker?

Accepted Answer

Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Biogen stocks are traded under the ticker BIIB.

Question 3

Is BIIB stock price going up?

Accepted Answer

BIIB stock has increased by 4.01% in the past week, has increased by 9.59% in the past month, and has increased by 68.08% in the past year. See more data on BIIB chart.

Question 4

What is the analyst recommendation for BIIB?

Accepted Answer

As of 29 Oct 2026, out of 20 analyst recommendations, the majority rate BIIB as a buy.

Question 5

What is BIIB market cap?

Accepted Answer

As of today, BIIB has the market capitalization of 37.34B USD. Explore our list of stocks ranked by market cap to compare BIIB with other stocks.

Question 6

Does BIIB release financial reports?

Accepted Answer

Yes, you can track BIIB financials in yearly and quarterly reports on Profit.com.

Question 7

When is BIIB next earnings date?

Accepted Answer

BIIB is going to release the next earnings report on -. Keep track of upcoming events with our Earnings Calendar.

Question 8

What were BIIB Earnings for the last quarter?

Accepted Answer

BIIB reported earnings of $3.6 per share for the last quarter, higher then the estimate of $3.04 per share, resulting in a 18.42% surprise. The estimated earnings for the next quarter are $2.06 per share. See more details about BIIB earnings on Profit.com.

Question 9

What was BIIB Revenue for the last quarter?

Accepted Answer

BIIB's revenue for the last quarter was 2.8B USD, higher then the estimated 2.62B USD. The estimated revenue for the next quarter is 2.59B USD See more stats in BIIB financial reports on Profit.com.

Question 10

What was BIIB Net Income for the last quarter?

Accepted Answer

BIIB net income for the last quarter is -20.6M USD, while the quarter before that showed 97.5M USD of net income which accounts for -121.13% change. See more stats in BIIB financial reports on Profit.com.

Question 11

Does BIIB pay dividends?

Accepted Answer

No, BIIB doesn't pay any dividends to its shareholders. But you can explore a list of high-dividend stocks on Profit.com.

Question 12

How many employees does BIIB have?

Accepted Answer

As of 29 Oct 2026, BIIB employs approximately 7500 employees. Check out if BIIB is on our list of largest employers.

Question 13

What is BIIB EBITDA?

Accepted Answer

EBITDA, which measures a company's operating performance, reflects its efficiency improvements. BIIB EBITDA is 3.36B USD, with a current EBITDA margin of 8.32%. See more stats in BIIB financial reports on Profit.com.

Question 14

How to buy BIIB stocks?

Accepted Answer

Like other stocks, BIIB shares are traded on stock exchanges such as NASDAQ. The easiest way to buy them is through an online stock broker. Simply open an account, follow the broker's procedures, and start trading. Alternatively, you can practice trading Tesla stock on Profit.com in Playtrade Tournaments or choose a recommended broker to trade directly.

Question 15

Should I invest in BIIB stock?

Accepted Answer

Investing in stocks requires thorough research, including analyzing the company’s financials, related news, and technical analysis. Currently, Tesla's technical analyst recommendations show a buy rating.

Before investing in BIIB, consider subscribing to Profit PRO where can practice trading in Playtrade Tournaments, access AI-powered daily market insights, copy expertly handpicked Watchlists, and follow Billionaire Portfolios.

Biogen Inc

Biogen to acquire RayThera in deal valued up to $1B

Apellis surges on $5.6B buyout deal with Biogen

Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy

Sage Therapeutics rejects Biogen bid, starts strategic review

Sage sues Biogen in wake of $469M buyout offer: report

Biogen and Belgian partner UCB announce positive data from late-stage trial of lupus treatment

Drugmaker Biogen boosts profit outlook on ‘momentum’ for new drugs

Biogen beats expectations, hikes outlook as Alzheimer's drug Leqembi and other new products gain traction

Sage Therapeutics’ stock dives as failed trial hits Biogen collaboration

IGM Biosciences up 40% following Biogen HI-Bio buy

Biogen inks $1.8B deal to acquire immune drug developer HI-Bio

Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments

Biogen drops controversial Alzheimer’s drug

China approves Alzheimer's treatment Leqembi by Eisai and Biogen https://t.co/L6fn9ObDxr https://t.co/bM0VWP0qdN

Biogen quarterly results top estimates despite complex launch of new Alzheimer’s treatment

Biogen and Eisai release new Alzheimer’s drug data that may support wider uptake

Reata shareholders clear buyout deal with Biogen

Reata Pharmaceuticals climbs as HSR waiting period for sale to Biogen expired

Biogen in $1.5B unsecured loan facility for Reata acquisition

Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion to boost its rare-disease offering

Larimar, Design higher as they benefit from Biogen deal for Reata

Biogen agrees to buy Reata Pharmaceuticals in deal valued at $7.3B

Biogen to slash 1,000 jobs as it looks to save $700 million

Biogen to cut 1,000 jobs to save costs as company prepares for Leqembi launch

Stocks making the biggest moves midday: Rivian, Levi Strauss, Biogen, First Solar and more

US FDA grants standard approval of Eisai/Biogen Alzheimer's drug https://t.co/dPTZVWV7nY https://t.co/tJhiKLMMhK

Movers & Shakers: Biogen stock climbs on drug approval recommendation, Oracle shares rise ahead of earnings, and other stocks on the move

FDA advisers vote in favor of Biogen and Eisai’s collaborative Alzheimer’s treatment

Eisai-Biogen Alzheimer's drug data confirms benefits, FDA staff says https://t.co/B8zM9OuUMN https://t.co/kBnCzNJITx

Eisai-Biogen Alzheimer's drug data confirms benefits, FDA staff says https://t.co/rT7SXVtPut https://t.co/xEscFEsucz

Eisai, Biogen Alzheimer's drug Leqembi would cost US Medicare up to $5 bln a year, study finds https://t.co/PPwucQj4cX https://t.co/jc4T3ZHDl7

Eisai, Biogen Alzheimer's drug Leqembi would cost US Medicare up to $5 bln a year, study finds https://t.co/FVizSAXwgQ https://t.co/ZsPKuBM8R7

Eisai, Biogen Alzheimer's drug Leqembi would cost US Medicare up to $5 bln a year, study finds https://t.co/4EKjVSspfk https://t.co/nBrtuI75sw

Biogen isn't concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says

Millions of Americans are expected to test for Alzheimer’s disease – some with at-home DNA test kits, others at labs — as new drugs for early Alzheimer’s, from partners Eisai and Biogen and Eli Lilly, usher in sweeping changes in treatment https://t.co/D1Ny08kJSN https://t.co/JgfEBUurn0

US FDA advisers to weigh full approval for Eisai-Biogen's Alzheimer's drug https://t.co/sx3nKxLoYv https://t.co/wxL63AqsHx

Pfizer, Biogen among hundreds of US drugmakers calling for abortion pill ruling reversal https://t.co/nKnJKMfnHr https://t.co/yjm0WBw4GW

US FDA advisers to weigh full approval for Eisai-Biogen's Alzheimer's drug https://t.co/MysxC06M8V https://t.co/jxvX3Sw1y5

Eisai, Biogen say FDA grants priority review for Alzheimer's drug Lecanemab https://t.co/eRoU2JxunD https://t.co/VAzT0W4iCb

Eisai, Biogen say FDA grants priority review for Alzheimer's drug Lecanemab https://t.co/Ym1X51nVBV https://t.co/9NTKMbzI1r

Eisai, Biogen say FDA grants priority review for Alzheimer's drug Lecanemab https://t.co/Bysx8mHeA4 https://t.co/bpjbjrlj87

Eisai, Biogen say Alzheimer's drug Lecanemab getting priority review in China https://t.co/8L0q1rOVxR https://t.co/L0KELgN969

Biogen CEO bets on Alzheimer's drug, pipeline to return to growth https://t.co/Fyg7ni9vv2 https://t.co/nPYonFlBKc

Biogen CEO bets on Alzheimer's drug, pipeline to return to growth https://t.co/GORyQxXcGd https://t.co/j4pNpDagY6

Biogen sees modest 2023 revenue from Alzheimer's disease drug https://t.co/XL1BwDKqTw https://t.co/uqdedtLHPw

Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen https://t.co/Wh8Tcs5azk https://t.co/5J5pZ9use9

Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen https://t.co/kTrEVHePch https://t.co/8oM6hrjRR5

Japan grants priority review status to Alzheimer's treatment from Eisai-Biogen https://t.co/wRxWzvIfq7 https://t.co/GrwduIAOfK

EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen https://t.co/JiSVeEebG6 https://t.co/5R3pEbciD4

FAQs